FRIDAY, Jan. 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain ...

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.

The FDA approved Journavx, the first new pain medication in over 20 years, as a non-opioid alternative for post-surgery pain. The drug, developed by Vertex Pharmaceuticals, blocks pain signals before ...

While America retains a gold standard for airline safety, there are stresses on the US air travel system that have been ...

In a significant development, federal officials have approved a new pain management medication, Journavx, aiming to mitigate the risks associated with opioid use, such as addiction and overdose. The U ...

The FDA has approved Vertex’s suzetrigine (Journavx), an oral inhibitor of voltage-gated sodium channel 1.8 (Na V 1.8), for the treatment of moderate to severe acute pain. The decision provides ...

Even if pain medications would incur a risk of hastening death, Jewish law permits – and even mandates – administering the ...

suitable for web design, banner, mobile app, landing page. Falling pills isolated on white background. 3d illustration Falling pills isolated on white background. 3d illustration pills on white stock ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.

The long quest for powerful non-opioid drugs that treat pain without risk of addiction is nearing a milestone, in the form of a pill that could soon win approval from the Food and Drug Administration.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

So, the Little Liver Pills had broad-based effect​, some of which might actually have referred to the liver. Well, no matter, ...